Pacira Biosciences, Stock Performance
| PCRX Stock | USD 16.64 0.14 0.83% |
Pacira BioSciences, has a performance score of 4 on a scale of 0 to 100. The company holds a Beta of 1.09, which implies a somewhat significant risk relative to the market. Pacira BioSciences, returns are very sensitive to returns on the market. As the market goes up or down, Pacira BioSciences, is expected to follow. Pacira BioSciences, right now holds a risk of 2.39%. Please check Pacira BioSciences, downside variance, and the relationship between the total risk alpha and daily balance of power , to decide if Pacira BioSciences, will be following its historical price patterns.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Pacira BioSciences, are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, Pacira BioSciences, may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
One Day Return (0.83) | Five Day Return (4.42) | Year To Date Return (48.00) | Ten Year Return (82.28) | All Time Return 137.04 |
1 | Disposition of 5773 shares by Lauren Riker of Pacira Pharmaceuticals at 38.52 subject to Rule 16b-3 | 09/10/2024 |
2 | Disposition of 500 shares by Daryl Gaugler of Pacira BioSciences, at 12.86 subject to Rule 16b-3 | 09/13/2024 |
3 | Pacira wins Exparel Medicare J-code | 10/03/2024 |
4 | Disposition of 1066 shares by Pace Gary W of Pacira BioSciences, at 29.67 subject to Rule 16b-3 | 10/11/2024 |
5 | Acquisition by Brege Laura of 1000 shares of Pacira BioSciences, at 12.81 subject to Rule 16b-3 | 10/25/2024 |
6 | Analysts Estimate Moderna to Report a Decline in Earnings What to Look Out for | 10/31/2024 |
7 | Acquisition by Shawn Cross of 75000 shares of Pacira BioSciences, subject to Rule 16b-3 | 11/01/2024 |
8 | Acquisition by Shawn Cross of 200000 shares of Pacira BioSciences, at 16.45 subject to Rule 16b-3 | 11/04/2024 |
9 | Pacira BioSciences Inc Q3 2024 Everything You Need To Know Ahead Of Earnings | 11/05/2024 |
10 | Pacira Q3 Earnings Snapshot | 11/06/2024 |
11 | Pacira BioSciences Inc Q3 2024 Earnings Call Highlights Strong Financial Position ... | 11/07/2024 |
12 | Pacira BioSciences Buy Rating Reiterated at Needham Company LLC | 11/11/2024 |
13 | Pacira BioSciences SWOT analysis stock faces patent challenges amid growth initiatives | 11/13/2024 |
14 | Pacira BioSciences, Inc. Shares Sold by Global Alpha Capital Management Ltd. - MarketBeat | 11/20/2024 |
15 | Pacira BioSciences Inc Shares Gap Down to 16.49 on Nov 26 | 11/26/2024 |
| Begin Period Cash Flow | 104.1 M |
Pacira |
Pacira BioSciences, Relative Risk vs. Return Landscape
If you would invest 1,556 in Pacira BioSciences, on August 30, 2024 and sell it today you would earn a total of 108.00 from holding Pacira BioSciences, or generate 6.94% return on investment over 90 days. Pacira BioSciences, is currently generating 0.1328% in daily expected returns and assumes 2.3853% risk (volatility on return distribution) over the 90 days horizon. In different words, 21% of stocks are less volatile than Pacira, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pacira BioSciences, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pacira BioSciences,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Pacira BioSciences,, and traders can use it to determine the average amount a Pacira BioSciences,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0557
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | PCRX | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.39 actual daily | 21 79% of assets are more volatile |
Expected Return
| 0.13 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Pacira BioSciences, is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pacira BioSciences, by adding it to a well-diversified portfolio.
Pacira BioSciences, Fundamentals Growth
Pacira Stock prices reflect investors' perceptions of the future prospects and financial health of Pacira BioSciences,, and Pacira BioSciences, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pacira Stock performance.
| Return On Equity | -0.11 | ||||
| Return On Asset | 0.0417 | ||||
| Profit Margin | (0.13) % | ||||
| Operating Margin | 0.13 % | ||||
| Current Valuation | 958.94 M | ||||
| Shares Outstanding | 46.17 M | ||||
| Price To Earning | 14.34 X | ||||
| Price To Book | 1.02 X | ||||
| Price To Sales | 1.11 X | ||||
| Revenue | 674.98 M | ||||
| Gross Profit | 393.23 M | ||||
| EBITDA | 157.58 M | ||||
| Net Income | 41.95 M | ||||
| Cash And Equivalents | 316.39 M | ||||
| Cash Per Share | 6.90 X | ||||
| Total Debt | 586.04 M | ||||
| Debt To Equity | 1.10 % | ||||
| Current Ratio | 3.95 X | ||||
| Book Value Per Share | 16.24 X | ||||
| Cash Flow From Operations | 154.65 M | ||||
| Earnings Per Share | (1.96) X | ||||
| Market Capitalization | 774.79 M | ||||
| Total Asset | 1.57 B | ||||
| Retained Earnings | (106.8 M) | ||||
| Working Capital | 412.61 M | ||||
| Current Asset | 252.58 M | ||||
| Current Liabilities | 149.79 M | ||||
About Pacira BioSciences, Performance
Evaluating Pacira BioSciences,'s performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Pacira BioSciences, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pacira BioSciences, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 206.25 | 118.98 | |
| Return On Tangible Assets | 0.05 | 0.05 | |
| Return On Capital Employed | 0.06 | 0.06 | |
| Return On Assets | 0.03 | 0.03 | |
| Return On Equity | 0.05 | 0.05 |
Things to note about Pacira BioSciences, performance evaluation
Checking the ongoing alerts about Pacira BioSciences, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Pacira BioSciences, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Pacira BioSciences Inc Shares Gap Down to 16.49 on Nov 26 |
- Analyzing Pacira BioSciences,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pacira BioSciences,'s stock is overvalued or undervalued compared to its peers.
- Examining Pacira BioSciences,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pacira BioSciences,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pacira BioSciences,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Pacira BioSciences,'s stock. These opinions can provide insight into Pacira BioSciences,'s potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.